Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab combinations for recurrent or metastatic cervical cancer
ChiCTR2300076740Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab, disitamab vedotin and paclitaxel in Cervical Cancer (CC) (2 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: objective response rate. Started Nov 2023; status: recruiting.
02
Drugs
cadonilimabdisitamab vedotinpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2300076740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076740.